Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis

Phase 3 Completed 90 enrolled Department of Medical Services Ministry of Public Health of Thailand

RandomizedCrossoverQuadruple-blindTreatment

Summary

To investigate that olanzapine can reduced side effect about nausea and vomiting in women with gynecologic cancers receiving carboplatin-based regimen by using olanzapine and placebo

Timeline

Start: 2020-03-01
Primary completion: 2021-06-30
Completion: 2021-09-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Olanzapine	Small molecule	5 mg	Oral
Subject	Olanzapine	Small molecule	10 mg	Oral

Indications

No indication recorded.